Oxford Transplant Centre, Churchill Hospital, Oxford, OX3 7LE
I studied medicine at Cambridge and St Thomas’s Hospital and after qualifying trained as a surgeon in London and Cambridge before undertaking a period of research at the University of Cambridge under the supervision of Professor Sir Roy Calne.
In 1988 I was appointed Visiting Assistant Professor of Surgery at Indiana University Medical Center, USA, where I was responsible for initiating a programme of liver transplantation. I returned to the UK in 1989 to take up the post of University Lecturer (honorary consultant) in the University Department of Surgery at Cambridge. I was the Clinical Director of the Cambridge Transplant Unit and also a Fellow and Director of Studies in Medicine at Magdalene College, Cambridge. I was appointed to my current post in 1999.
Professor of Transplantation
- Consultant Transplant and HPB Surgeon
- Director Oxford Transplant Centre
My experimental interest is in the application of isolated perfusion of the liver to a number of therapeutic areas. In particular, perfusion of the liver with oxygenated blood at normal body temperature can allow recovery from damage, extended preservation for transplantation and organ specific delivery of therapy.
Clinical research studies include small scale pilot studies of novel immunosuppressive strategies and the organisation of a multi centre national trial.
Multi-day perfusion of transplant organs: The how and the why
Sagar A. and Friend P., (2022), Med, 3, 442 - 444
The Effect of the COVID-19 Pandemic in Intestinal Rehabilitation and Transplant Patients: Initial Results of the Intestinal Rehabilitation and Transplant Association's International Survey
Segovia M. et al, (2022), Transplantation, 106, 1289 - 1292
In-situ normothermic regional perfusion versus ex-situ normothermic machine perfusion in liver transplantation from donation after circulatory death.
Mohkam K. et al, (2022), Liver Transpl
Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients.
Brook MO. et al, (2022), BMJ Open, 12
SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients.
Shankar S. et al, (2022), J Am Soc Nephrol